Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim..
PURPOSE: Although the pathophysiological response of cardiac tissue to pro-hypertrophic stimulus is well characterized, a comprehensive characterization of the molecular events underlying the pathological hypertrophy in cardiomyocytes during the early compensated cardiac hypertrophy is currently lacking.
EXPERIMENTAL DESIGN: A quantitative label-free proteomic analysis of cardiomyocytes isolated was conducted from mice treated subcutaneously with isoproterenol (ISO) during 7 days in comparison with cardiomyocytes from control animals (CT).
RESULTS: Canonical pathway analysis of dysregulated proteins indicated that ISO-hypertrophy drives the activation of actin cytoskeleton and integrin-linked kinase (ILK) signaling, and inhibition of the sirtuin signaling. Alteration in cardiac contractile function and calcium signaling are predicted as downstream effects of ISO-hypertrophy probably due to the upregulation of key elements such as myosin-7 (MYH7). Confocal microscopy corroborated that indeed ISO-treatment led to increased abundance of MYH7. Potential early markers for cardiac hypertrophy as APBB1, GOLGA4, HOOK1, KATNA1, KIFBP, MAN2B2, and SLC16A1 are also reported.
CONCLUSIONS AND CLINICAL RELEVANCE: The data consist in a complete molecular mapping of ISO-induced compensated cardiac hypertrophy model at cardiomyocyte level. Marker candidates reported may assist early diagnosis of cardiac hypertrophy and ultimately heart failure.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Proteomics. Clinical applications - 14(2020), 4 vom: 17. Juli, Seite e2000017 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Parreira, Ricardo Cambraia [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.06.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/prca.202000017 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310863074 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310863074 | ||
003 | DE-627 | ||
005 | 20231225141020.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/prca.202000017 |2 doi | |
028 | 5 | 2 | |a pubmed24n1036.xml |
035 | |a (DE-627)NLM310863074 | ||
035 | |a (NLM)32506788 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Parreira, Ricardo Cambraia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.06.2021 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | ||
520 | |a PURPOSE: Although the pathophysiological response of cardiac tissue to pro-hypertrophic stimulus is well characterized, a comprehensive characterization of the molecular events underlying the pathological hypertrophy in cardiomyocytes during the early compensated cardiac hypertrophy is currently lacking | ||
520 | |a EXPERIMENTAL DESIGN: A quantitative label-free proteomic analysis of cardiomyocytes isolated was conducted from mice treated subcutaneously with isoproterenol (ISO) during 7 days in comparison with cardiomyocytes from control animals (CT) | ||
520 | |a RESULTS: Canonical pathway analysis of dysregulated proteins indicated that ISO-hypertrophy drives the activation of actin cytoskeleton and integrin-linked kinase (ILK) signaling, and inhibition of the sirtuin signaling. Alteration in cardiac contractile function and calcium signaling are predicted as downstream effects of ISO-hypertrophy probably due to the upregulation of key elements such as myosin-7 (MYH7). Confocal microscopy corroborated that indeed ISO-treatment led to increased abundance of MYH7. Potential early markers for cardiac hypertrophy as APBB1, GOLGA4, HOOK1, KATNA1, KIFBP, MAN2B2, and SLC16A1 are also reported | ||
520 | |a CONCLUSIONS AND CLINICAL RELEVANCE: The data consist in a complete molecular mapping of ISO-induced compensated cardiac hypertrophy model at cardiomyocyte level. Marker candidates reported may assist early diagnosis of cardiac hypertrophy and ultimately heart failure | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a cardiac hypertrophy | |
650 | 4 | |a cardiomyocyte | |
650 | 4 | |a isoproterenol | |
650 | 4 | |a mass spectrometry | |
650 | 4 | |a proteomics | |
650 | 7 | |a Actins |2 NLM | |
650 | 7 | |a Myh7 protein, mouse |2 NLM | |
650 | 7 | |a Proteome |2 NLM | |
650 | 7 | |a integrin-linked kinase |2 NLM | |
650 | 7 | |a EC 2.7.1.- |2 NLM | |
650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a Myosin Heavy Chains |2 NLM | |
650 | 7 | |a EC 3.6.4.1 |2 NLM | |
650 | 7 | |a Isoproterenol |2 NLM | |
650 | 7 | |a L628TT009W |2 NLM | |
700 | 1 | |a Gómez-Mendoza, Diana Paola |e verfasserin |4 aut | |
700 | 1 | |a de Jesus, Itamar Couto Guedes |e verfasserin |4 aut | |
700 | 1 | |a Lemos, Rafael Pereira |e verfasserin |4 aut | |
700 | 1 | |a Santos, Anderson Kennedy |e verfasserin |4 aut | |
700 | 1 | |a Rezende, Cristiana Perdigão |e verfasserin |4 aut | |
700 | 1 | |a Figueiredo, Henrique César Pereira |e verfasserin |4 aut | |
700 | 1 | |a Pinto, Mauro Cunha Xavier |e verfasserin |4 aut | |
700 | 1 | |a Kjeldsen, Frank |e verfasserin |4 aut | |
700 | 1 | |a Guatimosim, Silvia |e verfasserin |4 aut | |
700 | 1 | |a Resende, Rodrigo Ribeiro |e verfasserin |4 aut | |
700 | 1 | |a Verano-Braga, Thiago |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Proteomics. Clinical applications |d 2007 |g 14(2020), 4 vom: 17. Juli, Seite e2000017 |w (DE-627)NLM179368206 |x 1862-8354 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2020 |g number:4 |g day:17 |g month:07 |g pages:e2000017 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/prca.202000017 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2020 |e 4 |b 17 |c 07 |h e2000017 |